Trial · NCT00690612
Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
NCT00690612, Phase 3, Completed, AstraZeneca; results first posted 2011-06-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics). Trials, record NCT00690612. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00690612
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)
- NCT number
- NCT00690612
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 35 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Hypertension
- Interventions
- candesartan cilexetil
- First posted
- 2008-06-04
- Last updated
- 2011-07-12
- Results first posted
- 2011-06-29
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP). | Every 3 months- baseline to final visit | Blood pressure response was defined as Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) less than the 95th percentile based on population height-adjusted charts for age and gender. Response rates were based on the proportion of patients meeting the criteria at each evaluation time point or the last available measure. |
| Primary | Mean Change From Baseline to Final Visit in Diastolic Blood Pressure (DBP). | every 3 months - baseline to final visit | Blood pressure response was defined as Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) less than the 95th percentile based on population height-adjusted charts for age and gender. Response rates were based on the proportion of patients meeting the criteria at each evaluation time point or the last available measure. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP). | Every 3 months- baseline to final visit | Millimeters of Mercury (mm Hg) | MEAN | |
| PRIMARY | Mean Change From Baseline to Final Visit in Diastolic Blood Pressure (DBP). | every 3 months - baseline to final visit | mm Hg | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Change From Baseline to Final Visit in Systolic Blood Pressure (SBP). | Atacand Candesartan Cilexetil | -2.86 | Standard Deviation 11.97 | Millimeters of Mercury (mm Hg) | |
| Mean Change From Baseline to Final Visit in Diastolic Blood Pressure (DBP). | Atacand Candesartan Cilexetil | -0.43 | Standard Deviation 12.26 | mm Hg |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Atacand Candesartan Cilexetil | 35 | |
| Overall Study | COMPLETED | Atacand Candesartan Cilexetil | 32 | |
| Overall Study | NOT COMPLETED | Atacand Candesartan Cilexetil | 3 |
Source ClinicalTrials.gov
Adverse events24
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Diarrhoea | Gastrointestinal disorders | Atacand Candesartan Cilexetil | 6 | 35 | |
| other | Nausea | Gastrointestinal disorders | Atacand Candesartan Cilexetil | 3 | 35 | |
| other | VOMITING | Gastrointestinal disorders | Atacand Candesartan Cilexetil | 3 | 35 | |
| other | PYREXIA | General disorders | Atacand Candesartan Cilexetil | 9 | 35 | |
| other | FATIGUE | General disorders | Atacand Candesartan Cilexetil | 2 | 35 | |
| other | PHARYNGITIS | Infections and infestations | Atacand Candesartan Cilexetil | 6 | 35 | |
| other | RHINITIS | Infections and infestations | Atacand Candesartan Cilexetil | 6 | 35 | |
| other | NASOPHARYNGITIS | Infections and infestations | Atacand Candesartan Cilexetil | 4 | 35 | |
| other | BRONCHITIS | Infections and infestations | Atacand Candesartan Cilexetil | 3 | 35 | |
| other | UPPER RESPIRATORY TRACT INFECTION | Infections and infestations | Atacand Candesartan Cilexetil | 3 | 35 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Atacand Candesartan Cilexetil | ||
| Total, other adverse events | Atacand Candesartan Cilexetil | 28 | 35 |
| Total, serious adverse events | Atacand Candesartan Cilexetil | 3 | 35 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00690612
GET https://conductscience.org/api/trials/v1/NCT00690612/events?page=2